Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jung Won Shin
Korea May Adopt Further Cost-Containment Steps Under 'Moon Jae-In Care' – IQVIA
Robust Appetite For Biosolution IPO As OA Cell Therapy Nears Commercialization
Biosolution's IPO, which was priced at the high end of the range despite dampened biotech sentiment following the arrest of Nature Cell's CEO, is poised to help accelerate commercialization of the South Korean cell therapy company's osteoarthritis treatment CartiLife and the progress of other pipeline assets.
Nature Cell Mired In Uncertainty as CEO Arrested For Alleged Stock Price Manipulation
The Korean biotech’s CEO and several other executives’ alleged involvement in stock price manipulation using false and exaggerated information on a pipeline stem cell therapy has damaged the credibility of its R&D efforts and shocked the domestic industry, although their fate remains to be determined after court trials.
Korea Outlines Device Regulatory Reforms And Other Steps To Foster Medtech
Amid repeated calls from industry that South Korea’s medical device regulations must catch up with a rapidly changing industry, the country has unveiled measures to reform the rules and nurture the sector, including efforts to accelerate market entry of cutting-edge devices.
Yuhan Licenses Out Degenerative Disc Therapy To Spine Despite Earlier Trial Failure
South Korean pharma firm licenses out to US venture Spine Biopharma novel peptide drug for degenerative disc disease YH14618, despite a Phase II failure and trial halt in 2016.
Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.